Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%

Phio Pharmaceuticals Corp.

CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.
Annual target bonus opportunity raised from 40% to 50% of base salary.
Amendment effective Feb 17, 2026; equity vesting acceleration unchanged.
No other changes to existing employment agreement terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.